New combo therapy for rheumatoid arthritis shows promise in early trial

NCT ID NCT01143337

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether adding an experimental drug called MP-435 to standard methotrexate treatment helps people with rheumatoid arthritis who don't get enough relief from methotrexate alone. 112 adults took either MP-435 or a placebo (dummy pill) plus their usual methotrexate for 12 weeks. The main goal was to see if more people in the MP-435 group had at least a 20% improvement in joint pain, swelling, and daily function. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MP-435 (an experimental drug) plus methotrexate
What this could lead to
If it works, this could point toward a new treatment option for rheumatoid arthritis when methotrexate alone isn't enough.
What could go wrong
This is an early Phase 2 exploratory study with only 112 people. It may not show enough benefit or could have side effects. Success in this trial does not guarantee a future approved treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational site

    Osaka, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.